Accessibility Menu
 
United Therapeutics logo

United Therapeutics

(NASDAQ) UTHR

Current Price$523.26
Market Cap$23.34B
Since IPO (1999)+8,639%
5 Year+205%
1 Year+70%
1 Month-2%

United Therapeutics Financials at a Glance

Market Cap

$23.34B

Revenue (TTM)

$3.18B

Net Income (TTM)

$1.33B

EPS (TTM)

$27.90

P/E Ratio

19.09

Dividend

$0.00

Beta (Volatility)

0.45 (Low)

Price

$523.26

Volume

29,161

Open

$532.59

Previous Close

$523.26

Daily Range

$521.10 - $534.96

52-Week Range

$266.98 - $549.50

UTHR: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About United Therapeutics

Industry

Biotechnology

Employees

1,400

CEO

Martine A. Rothblatt, PhD, MBA

Headquarters

Silver Spring, MD 20910, US

UTHR Financials

Key Financial Metrics (TTM)

Gross Margin

88%

Operating Margin

47%

Net Income Margin

42%

Return on Equity

20%

Return on Capital

20%

Return on Assets

17%

Earnings Yield

5.24%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$23.34B

Shares Outstanding

43.83M

Volume

29.16K

Short Interest

0.00%

Avg. Volume

442.72K

Financials (TTM)

Gross Profit

$2.80B

Operating Income

$1.49B

EBITDA

$1.82B

Operating Cash Flow

$1.56B

Capital Expenditure

$520.50M

Free Cash Flow

$1.04B

Cash & ST Invst.

$1.56B

Total Debt

$0.00

United Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$790.20M

+7.4%

Gross Profit

$686.80M

+4.1%

Gross Margin

86.91%

N/A

Market Cap

$23.34B

N/A

Market Cap/Employee

$17.88M

N/A

Employees

1,305

N/A

Net Income

$364.30M

+20.9%

EBITDA

$524.30M

+23.6%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$1.56B

-47.5%

Accounts Receivable

$350.20M

+25.4%

Inventory

$183.10M

+16.0%

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

16.94%

N/A

Return on Invested Capital

20.39%

N/A

Free Cash Flow

$173.30M

-31.9%

Operating Cash Flow

$346.20M

+1.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DGXQuest Diagnostics Incorporated
$195.51-1.33%
RPRXRoyalty Pharma plc
$46.35-1.26%
BIIBBiogen Inc.
$183.84-3.78%
ILMNIllumina, Inc.
$117.67-5.41%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$38.78-0.06%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$8.28+0.05%
ARTLArtelo Biosciences
$10.54+2.30%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$11.56-0.06%

Questions About UTHR

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.